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Patients with acute myeloid leukemia (AML) who harbor internal tandem duplication (ITD) mutations of the
FMS-like tyrosine kinase 3 (FLT3) gene carry a poor prognosis. Although allogeneic transplantation may
improve outcomes, relapse occurs frequently. The FLT3/ITDmutation has been deemed an unsuitable minimal
residual disease (MRD) marker because it is unstable and because the standard assay for the mutation is
relatively insensitive. The FLT3 mutation is undetectable by PCR at pre- or post-transplant time points in
many FLT3/ITD AML patients who subsequently relapse after transplant. We report the application of a new
technique, tandem duplication PCR (TD-PCR), for detecting MRD in FLT3/ITD AML patients. Between October
2004 and January 2012, 54 FLT3/ITD AML patients in remission underwent transplantation at our institution.
Of 37 patients with available day 60 marrow samples, 28 (76%) were assessable for MRD detection. In seven of
28 patients (25%), the FLT3/ITDmutation was detectable by TD-PCR but not by standard PCR on day 60. Six of 7
patients (86%) with MRD by TD-PCR have relapsed to date compared with only 2 of 21 patients (10%) who
were negative for MRD (P ¼ .0003). The ability to detect MRD by this sensitive technique may provide an
opportunity for early clinical intervention.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
FMS-like tyrosine kinase 3 (FLT3) gene/internal tandem
duplication (ITD) mutations are present in approximately
one-fourth of adult acute myeloid leukemia (AML) cases.
Patients with these mutations carry a particularly poor
prognosis, with an estimated 4-year overall survival of app-
roximately 20% [1-4]. For this reason, a number of small-
molecule FLT3 inhibitors are currently being evaluated in
clinical trials. It has become an increasingly commonpractice
to pursue allogeneic bone marrow transplantation during
ﬁrst remission in patients with FLT3/ITD mutations [2,5-7].
Among the FLT3/ITDAML patient population, relapse after
transplant occurs frequently [8-10]. As a result, there are
numerous ongoing efforts to investigate the potential role ofdgments on page 1994.
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ty for Blood and Marrow Transplantation.maintenance therapy with FLT3 inhibitors in the post-
transplant setting. Historically, post-transplant remission in
AML patients has been assessed using bone marrow mor-
phology as well as hematologic recovery [11]. Morphologic
techniques, however, are insensitive, and better methods are
needed to assess minimal residual disease (MRD) in AML
patients.
Because FLT3 status can change over time, it has been
suggested that FLT3 mutational status may not be a good
marker for MRD in FLT3/ITD AML [12]. The standard method
of detecting the FLT3/ITD mutation with PCR has a limit of
detection of approximately 1 in 100 cells [13]. The relatively
low sensitivity of this assay is, in part, due to competition
between the mutant and wild-type alleles [13,14], which we
here refer to as PCR bias. The standard FLT3 PCR ampliﬁcation
product is signiﬁcantly longer in patients with the ITD
mutation than in patients with a wild-type FLT3 gene [15].
The shorter, wild-type ampliﬁcation product therefore will
be multiplied preferentially by PCR as compared with the
longer, mutant product. The FLT3 mutation is still not
Table 1
Patient Demographics
Characteristic Value
Number of Patients 54
Mean age, yr (standard deviation) 46 (13)
Number of male patients 20 (37%)
Relapsed/refractory AML before transplant 11 (20%)
Cytogenetics*
Favorable 1 (2%)
Intermediate 49 (91%)
Unfavorable 4 (7%)
Normal 36 (67%)
NPM1 mutational status
Positive 17 (31%)
Negative 7 (13%)
Unknown 30 (56%)
Preparatory regimen
Myeloablative 44 (81%)
Nonmyeloablative 10 (19%)
Type of transplant
Matched related 19 (35%)
Matched unrelated 15 (28%)
Mismatched unrelated 1 (2%)
Haploidentical 19 (35%)
* Cytogenetic risk was determined according to the classiﬁcation scheme
described in Blood 1998;92:2322-2333.
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after transplant in many FLT3/ITD AML patients who ulti-
mately relapse with FLT3-mutated disease after transplant,
because their burden of disease is lower than the detection
threshold of the standard assay. Thus, the change in FLT3
status may be due, at least in part, to the low sensitivity of
this assay.
The presence of pretransplant MRD by ﬂow cytometry is
known to carry an adverse prognosis [16]. In addition, in the
core binding factor leukemias and nucleophosmin (NPM1)
mutated AML, MRD as assessed by PCR has been shown to
predict relapse [17,18]. In spite of the widely held belief that
FLT3 status is not a good marker for MRD, multiple groups
have reported that identiﬁcation of MRD by FLT3 status using
patient-speciﬁc PCR serves as a marker of relapse [19-22].
However, patient-speciﬁc PCR is cumbersome to perform,
difﬁcult to standardize, and not routinely available outside of
a research setting.
A better method of MRD detection in FLT3/ITD AML
would be useful both for determining prognosis and for
guiding therapy, such as determining whether transplan-
tation should be performed and whether FLT3 inhibitors
should be introduced. We report here the retrospective
application of a novel technique, tandem duplication PCR
(TD-PCR), to a cohort of consecutive FLT3/ITD AML patients
who underwent allogeneic transplant at our institution,
allowing us to correlate the presence of the FLT3/ITD muta-
tion with clinical outcomes. Our analysis demonstrates that
the FLT3/ITDmutation is a useful marker for MRD and can be
used to guide clinical decision making for these patients,
potentially including the timely use of FLT3 inhibitors.
METHODS
Selection of Patients
We performed a chart review to evaluate all patients diagnosed with
FLT3/ITD AML between October 2004 and January 2012 who underwent
allogeneic bone marrow transplant at our institution while in morphologic
and immunophenotypic remission. Patients who had more than 5% blasts
by morphology or ﬂow cytometry immediately before transplant were
excluded from the analysis. Patients followed at our institution but trans-
planted elsewhere were also excluded.
Polymerase Chain Reaction
Conventional PCR for detecting an ITD mutation was performed as
previously described [13].
Tandem Duplication PCR
TD-PCR was modiﬁed from an original proof-of-principle version [23].
TD-PCR uses a pair of primers for ampliﬁcation but is oriented in the opposite
direction from standard PCR. This technique allows exponential ampliﬁcation
only when the targeted region is duplicated, in amanner analogous to inverse
PCR, thus eliminating the background wild-type amplicons obtained with
standard approaches and improving the limit of detection to a single mole-
cule. In our previous design, only ITD mutants with large duplications
extending into intron 14 could be ampliﬁed.We revised the design to improve
the clinical applicability of TD-PCR for MRD detection. We found that over-
lapping primers pointing in opposite directions sufﬁced for TD-PCR, partic-
ularly when a few bases were altered in each primer so primereprimer
annealing is disfavored. This design improved the capability of TD-PCR to
detect shorter ITD mutants, although duplications under 30 to 40 bases
remained too small to anneal both primers. With this approach, we con-
structed a series of 7 primer pairs that cover exon 14 and proximal intron 14.
The redesigned TD-PCR has a limit of detection of a single ITD molecule. In a
cohort of 58 newly diagnosed or relapsed FLT3/ITD AML patients, we found
that up to 70% of ITD mutants can be ampliﬁed by 1 or more of the 7 primer
pairs (MT Lin and CD Gocke, unpublished data).
For the current study, the initial diagnostic specimen of each patient
was ﬁrst testedwith all 7 primer pairs to determinewhichwere informative.
One or 2 informative primer pairs were subsequently used to test
pretransplant specimens and day 60 post-transplant bone marrow speci-
mens in quadruplicate (total 1 mg DNA examined, equivalent toapproximately 160,000 cells). PCR products were subjected to capillary
electrophoresis for analysis as described previously [23]. Of note, day 60 TD-
PCR results were not available to clinicians and therefore did not impact
clinical decision making in the patient population studied.
Statistics
The log rank test was used to assess differences in relapse-free survival
and overall survival between patients with positive TD-PCR and negative
TD-PCR results.
RESULTS
To assess whether it is possible to detect MRD at pre- and
post-transplant time points in FLT3/ITD AML patients, we
identiﬁed 54 patients who were diagnosed between October
2004 and January 2012 with FLT3/ITD AML, subsequently
underwent allogeneic bone marrow transplant while in
morphologic remission, survived the transplant, and were
conﬁrmed to be in complete remission (CR) with a bone
marrow biopsy obtained 60 days post-transplant. This group
represents a consecutive series of such patients from our
institution. The demographics of these patients are reported
in Table 1. Median duration of follow-up was 35.1 months.
All patients receiving myeloablative preparative regi-
mens received busulfan and cyclophosphamide, except 1
patient who received a myeloablative conditioning regimen
consisting of busulfan and ﬂudarabine. All patients receiving
nonmyeloablative regimens were treated with ﬂudarabine,
cyclophosphamide, and total body irradiation. For graft-
versus-host disease (GVHD) prophylaxis, all patients recei-
ved post-transplant cyclophosphamide. For myeloablative
matched related and unrelated donor transplants, no further
prophylaxis was administered. For myeloablative haploi-
dentical transplants, patients received tacrolimus through
day þ180. For nonmyeloablative transplants, patients recei-
ved tacrolimus through day þ180 and mycophenolate
mofetil through day þ35.
Of the 54 patients studied, 23 patients (43%) were alive
and in remission at the time of data analysis and 13 (24%)
had died of transplant-related toxicity. One patient (2%) died
of an unknown cause, thought likely to be related to relapse
of an underlying myeloproliferative neoplasm. Seventeen
patients (31%) relapsed after transplant (6 of whomwere still
Table 2
FLT3 TD-PCR Results for 28 Assessable Patients
Patient Number Pretransplant TD-PCR
Result
Post-Transplant TD-PCR Result
(Day 60)
Duration of Follow-Up
(days)
Outcome
1 e e 1185þ Alive, in remission
2 þ þ 589þ Alive, but relapsed
3 þ e 225 Death due to toxicity
4 þ e 2376þ Alive, in remission
5 þ e 1732þ Alive, in remission
6 þ e 821þ Alive, in remission
7 e e 542þ Alive, in remission
8 þ e 751þ Alive, in remission
9 þ þ 844 Death due to AML
10 þ e 2024þ Alive, in remission
11 þ þ 656 Death due to AML
12 e e 3048þ Alive, in remission
13 þ e 1645þ Alive, in remission
14 þ e 541þ Alive, in remission
15 þ e 826þ Alive, in remission
16 þ e 979þ Alive, in remission
17 e e 343 Death due to toxicity
18 þ e 1341þ Alive, in remission
19 e e 505 Death due to toxicity
20 e e 2456þ Alive, in remission
21 þ þ 735 Death due to AML
22 e e 1162þ Alive, in remission
23 þ þ 602þ Alive, but relapsed
24 þ e 597 Death due to AML
25 þ e 1039þ Alive, in remission
26 þ þ 463 Death due to AML
27 No sample e 1585 Death due to AML
28 þ þ 1855þ Alive, in remission
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patients, 16 (94%) harbored the identical FLT3/ITD mutation
present at diagnosis, as detected by the standard clinical PCR
assay for FLT3 mutations. DNA samples prepared from bone
marrow collected at day 60 were available for 37 of 54 pa-
tients (69%). Because of the lengths of patients’ ITDs, the FLT3
TD-PCR assay was informative for 28 of 37 patients (76%)
with available samples. FLT3 TD-PCR results for these 28
patients are shown in Table 2. Outcomes and MRD results
for the 28 assessable patients are shown in Figure 1. At the
time of transplantation, 24 of 28 assessable patients were in
CR. Three patients were in CR with incomplete platelet re-
covery. One patient was in CR with incomplete hematologic
recovery.
Among the 28 patients, 7 (25%) were positive for MRD by
FLT3 TD-PCR on their day 60 bone marrow specimens. The
standard clinical PCR for FLT3 mutation was performed and
was negative in all 7 cases. Of these 7 patients, 6 (86%) have
relapsed to date, whereas 1 (14%) remains in remission
1855 days after transplant. The remaining 21 assessableFigure 1. MRD results and outcomepatients (75%) were negative for MRD by TD-PCR on their day
60 bone marrow specimens. Of these 21 patients, only 2
(10%) have relapsed.
In the total population of 54 transplanted patients,median
estimated relapse-free survival is 15.0 months (Figure 2A).
Median overall survival is 27.7 months (Figure 2B). Among
the 28 patients with assessable results, evidence of MRD
by FLT3 TD-PCR was highly prognostic (P ¼ .0003) of relapse
after allogeneic transplant (Figure 3A). Overall survival by
TD-PCR status is shown in Figure 3B.
The results shown in Figure 3 indicate that FLT3/ITD
mutations can be used as important markers of MRD. In
interpreting our ﬁndings, we noted that patients could be
divided byMRD status (as determined by FLT3 TD-PCR) into 3
groups, each with unique characteristics.
Group 1: Patients Negative for Pretransplant MRD and
Negative for Post-Transplant MRD
Of the 7 patients who were negative for MRD both before
transplant and at day 60, none (0%) has relapsed. One patients for 28 assessable patients.
Figure 2. (A) Relapse-free survival in 54 FLT3/ITD AML patients undergoing
transplant at a single institution. (B) Overall survival in 54 FLT3/ITD AML
patients undergoing transplant at a single institution.
Figure 3. (A) Relapse-free survival by day 60 TD-PCR status. (B) Overall sur-
vival by day 60 TD-PCR status.
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cytomegalovirus pneumonitis approximately 10 months
after transplant. No patient with a negative pretransplant
MRD assay became positive for MRD after transplant.Group 2: Patients Positive for Pretransplant MRD and
Negative for Post-Transplant MRD
Unlike patients who were negative for MRD before
transplant, some patients with positive pretransplant MRD
assays underwent conversion of their MRD status post-
transplant. Of the 20 patients with positive pretransplant
MRD assays, 13 (65%) were negative for MRD by FLT3 TD-PCR
at day 60. Of these 13 patients, only 1 (patient 24 in Table 2)
has relapsed. This patient had an ITD allele burden of less
than 5% in the initial diagnostic specimen and relapsed
approximately 10 months after transplant. Interestingly,
this patient relapsed without the ITD mutation by either
the standard assay or TD-PCR. Of the other 12 patients who
converted from positive MRD status pretransplant to nega-
tive MRD status post-transplant, 11 are alive and in remission
and 1 died of sepsis 4 months after transplant.
One patient (patient 27) did not have a pretransplant
bone marrow sample available. This patient had a nega-
tive post-transplant MRD assay at day 60, but a marrow
sample collected 12 months after transplant was positive
by TD-PCR for the FLT3/ITD mutation. This patient relapsed
(with the FLT3/ITD mutation) 28 months after transplant,
suggesting the presence of this MRD marker heralds
relapse.Group 3: Patients Positive for Pretransplant MRD and
Positive for Post-Transplant MRD
Seven of 20 patients (35%) who were positive for pre-
transplant MRD continued to be positive for MRD by FLT3
mutational status at day 60 after transplant. Six of these
patients (86%) have relapsed. One patient (patient 28) who
was positive for the FLT3/ITD mutation at pre- and post-
transplant time points has not relapsed. This patient devel-
oped cutaneous GVHD and has now been in remission more
than 4 years. The ITD mutation was not detected by TD-PCR
in bone marrow specimens from 1-year and 3-year post-
transplant time points, potentially indicative of a graft-
versus-leukemia effect.
Five of 6 patients with post-transplant MRD by TD-PCR
who ultimately relapsed underwent bone marrow aspirate
and biopsy at the time of relapse. Among these 5 patients, 4
had metaphase cytogenetics identical to the metaphase
cytogenetics seen at diagnosis. One patient with normal
cytogenetics at diagnosis had an additional copy of chro-
mosome 13 at relapse.Patients who Received FLT3 Inhibitors in the Peri-
Transplant Setting
Having established that TD-PCR represents a sensitive,
convenient assay for MRD in FLT3/ITD patients, the question
arises as to what type of clinical intervention could be per-
formed when MRD is detected. FLT3 inhibitors represented
an obvious possibility. We therefore examined our dataset
for patients who received FLT3 inhibitors in the peritrans-
plant setting.
Three patients received small-molecule FLT3 inhibitors in
the peritransplant setting. Patient 2, who was positive for
MRD both pre- and post-transplant, received sorafenib as
post-transplant maintenance therapy on a clinical trial from
4 months until 12 months after transplantation. Sorafenib
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in which the patient was on sorafenib, retrospective testing
revealed the patient had been positive for the FLT3/ITD mu-
tation by TD-PCR, despite being in clinical/morphologic
remission and despite the standard clinical assay for FLT3
remaining negative. The patient relapsed with FLT3/ITD AML
1 month after discontinuing sorafenib (Figure 4).
Patient 21, whowas positive forMRD by FLT3 TD-PCR both
before and after transplant, received FLT3 inhibitors on 2
occasions. The patient received the FLT3 inhibitor quizartinib
as a single agent on a clinical trial, ultimately achieving
a morphologic remission on this drug before transplant.
The patient was initiated on off-label sorafenib approxi-
mately 3 months after transplant as maintenance therapy.
The patient self-discontinued sorafenib after approximately
6 weeks on this medication. A bone marrow biopsy 3 weeks
after stopping sorafenib revealed AML in early relapse, with
morphologic evidence of disease (approximately 4% of cells
were leukemic blasts) and with the presence of the FLT3/ITD
mutation detectable by standard PCR.
Patient 25was positive for MRD both by standard PCR and
by FLT3 TD-PCR before transplant. As a precaution to prevent
relapse before transplant, this patient received sorafenib for
approximately 1 month before the start of the transplant
preparative regimen. The patient was negative for MRD by
TD-PCR at day 60 after transplant. The patient did not receive
a FLT3 inhibitor after transplant but experienced grade II
GVHD and remains in remission approximately 30 months
after transplant.
DISCUSSION
Given the poor prognosis of patients with FLT3/ITD AML
and recent reports of some success with allogeneic bone
marrow transplantation, transplant has become the standard
of care for this disease [2,5-7]. However, there remains aFigure 4. TD-PCR detected MRD at 2 months post-transplant and predicted relapse. In
420 bases at 13 months post-transplant (C) but not at 2 months (A) or 12 months (B) p
ITD mutant at 2 (D and G), 12 (E and H), and 13 months (F and I) post-transplant. TD
before electrophoresis. The red vertical lines indicate off-scale peaks. Arrows indicat
parentheses). RFU indicates relative ﬂuorescence units.signiﬁcant relapse rate after transplant for FLT3/ITD AML.
Thus, it would be useful to have a marker for the presence
of MRD in patients after transplant. Such a prognostic bio-
marker might help guide early intervention with a strategy
such as FLT3 inhibition and/or alteration in GVHD prophy-
laxis in patients who are at high risk for relapse.
Investigators have questioned whether FLT3 mutational
status is an adequate marker for MRD in FLT3/ITD AML
patients receiving chemotherapy and/or undergoing alloge-
neic transplant. For instance, it has been shown in multiple
studies that the FLT3/ITD mutational status of AML patients
can be different at relapse than at diagnosis [24-26]. Not only
can FLT3/ITD patients relapse without the ITD mutation, but
AML patients without themutation can relapsewith FLT3/ITD
AML. This phenomenon is not unique to FLT3/ITD AML and
also applies to other mutations occurring in leukemia,
including N-ras and p53 mutations [24]. It has been argued
that because of this “instability” of FLT3 mutations, FLT3/ITD
mutational status is not a valuable indicator of MRD or pre-
dictor of relapse [12].
In spite of the potential for an AML patient’s FLT3/ITD
mutational status to change over time, such alterations are
not common. Among patients who are FLT3/ITD negative at
diagnosis, approximately 10% acquire themutation at relapse
[12]. When relapse occurs in patients harboring the FLT3/ITD
mutation at diagnosis, the mutation is present in most cases.
In one study, 13 of 16 relapsing FLT3/ITD AML patients (81%)
relapsed with the ITD [12]. In another report, 16 of 17 FLT3/
ITDAML patients (94%) who relapsed had the ITDmutation at
relapse [26], which is identical to what we found in the
present study.
Our ﬁndings are similar to those of prior studies using
patient-speciﬁc PCR for detection of FLT3/ITD mutational
status [19-22]. A signiﬁcant advantage of FLT3 TD-PCR,
however, is that it uses standardized primers rather thanpatient 2, standard PCR showed relapse of the original ITD mutant migrating at
ost-transplant. TD-PCR using primer pairs TD3 and TD7, however, detected the
-PCR products from the relapse specimen at 13 months were diluted 30-fold
e amplicons from the same ITD mutant (with sizes in nucleotides provided in
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clinical laboratory. Our results conﬁrm that post-transplant
MRD by FLT3 mutational status predicts relapse in FLT3/ITD
AML patients. Because all 7 patients who were negative for
MRD before transplant remained negative at day 60 after
transplant and did not relapse, a negative pretransplant MRD
assay appears to be quite meaningful.
Of the 21 patients who were negative for MRD at day 60,
the 2 who ultimately relapsed both had informative courses.
Patient 24 relapsed with FLT3 wild-type AML. Given this
patient had an ITD allelic burden of less than 5% at diagnosis,
it is likely the FLT3/ITDmutation represented a nondominant
subclone in this patient. Although this patient’s case might
be interpreted as corroborating the warnings of those who
are wary of using FLT3 mutational status as a test for MRD,
the changing of a patient’s FLT3 status appears to interfere
with MRD detection in only a small proportion of patients.
The “instability” of FLT3 mutations therefore represents a
relatively uncommon limitation of using FLT3 status to
determine MRD. Patient 27, the other patient who was
negative for MRD at day 60 but relapsed, had converted to
positive by the 12-month mark and ultimately relapsed with
FLT3/ITD AML. This patient’s relapse at 28 months was the
latest relapse among our patients. Thus, based on a limited
sample, it appears that a negative day 60 post-transplant
MRD assay suggests relapse is unlikely. Moreover, the
case of patient 27 suggests it may be useful to continue
monitoring for MRD after day 60, because it is possible this
patient would have beneﬁtted from therapy with an FLT3
inhibitor at the time of conversion from MRD negative to
MRD positive.
There are also instructive cases of patients who
were positive for the FLT3/ITDmutation on day 60. Patient 28
had a positive day 60 MRD assay and remains in a durable
remission. This individual’s case provides evidence that a
graft-versus-leukemia effect can occur after day 60. Patient
2 also was positive for the FLT3/ITD mutation at day 60.
Although treated with sorafenib, this patient remained in
remission until approximately 12 months after transplant
and relapsed quickly upon discontinuation of this drug,
suggesting FLT3 inhibition may have a role in maintenance
therapy for some patients with FLT3/ITD AML after allogeneic
transplant, much in the same way that BCR-ABL inhibition is
used in Philadelphia chromosome positive acute lympho-
blastic leukemia.
Sustained remissions have been reported with the
FLT3 inhibitor sorafenib administered as monotherapy after
transplant [27]. However, using sorafenib after post-
transplant relapse does not always appear to be an effec-
tive strategy [28]. Currently, investigators are working to
identify patients early who may be at high risk for relapse
and likely to beneﬁt from post-transplant FLT3 inhibition.
Studies have suggested that sorafenib, in combination with
the allogeneic immune effects of transplant, may induce
durable remissions in some patients [27]. It is possible
that MRD by FLT3/ITDmutational status will identify patients
who may beneﬁt from post-transplant therapy such as FLT3
inhibition, withdrawal of GVHD prevention, or donor lym-
phocyte infusion. We are currently examining the use of
TD-PCR prospectively in an ongoing clinical trial using post-
transplant sorafenib in FLT3/ITD AML patients.
One signiﬁcant limitation of the TD-PCR technique is
the inability of the assay to be informative in FLT3/ITD AML
patients with shorter ITDs, which account for approximately
25% of FLT3/ITD AML cases. Moreover, in our study, bonemarrow DNA specimens were not available for 17 patients in
our cohort of FLT3/ITD AML patients undergoing transplant.
Furthermore, the TD-PCR technique does not overcome
instability of some patients’ FLT3 mutational status, which
remains an important challenge to ﬁnding an optimal MRD
marker. In spite of these limitations, our ﬁndings reveal that
FLT3 mutational status can be useful in detecting MRD. In
addition, to our knowledge, this study represents the largest
consecutive series of FLT3/ITD AML patients undergoing
transplant at a single institution.
In summary, our results support the use of FLT3/ITD
mutational status by TD-PCR as a marker for MRD. The FLT3
TD-PCR technique, with deﬁned primer sets, would be rela-
tively simple to adopt as a standard assay in clinical labora-
tories. Given the present study has been performed using
bone marrow samples, one future direction of this work will
be to determine whether the TD-PCR assay is predictive
using peripheral blood, which would render the assay more
convenient to perform. Prospective studies will likely be
necessary to validate MRD assessed by FLT3 TD-PCR as a
prognostic instrument and as a means of guiding therapy.
ACKNOWLEDGMENTS
Financial disclosure: Supported in part by R21HG004315
(to C.D.G.) and R21HG005745 (to C.D.G.) from the National
Institutes of Health. This work was also supported by the MD
Anderson leukemia SPORE P50 CA100632 (to M.J.L.) and by
the Johns Hopkins Oncology institutional training grant from
the National Institutes of Health, 2T32CA009071-32 (to
M.R.G.).
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Authorship statement: M.R.G. and L.-H.T. contributed
equally to this manuscript.
REFERENCES
1. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic signiﬁcance
of, and gene and microRNA expression signatures associated with,
CEBPA mutations in cytogenetically normal acute myeloid leukemia
with high-risk molecular features: a Cancer and Leukemia Group B.
Study. J Clin Oncol. 2008;26:5078-5087.
2. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment
outcome in cytogenetically normal acute myeloid leukemia. N Engl J
Med. 2008;358:1909-1918.
3. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia. 2003;17:
1738-1752.
4. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the ﬂt3
gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918.
5. DeZern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for
FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive
newly diagnosed patients from a single institution. Biol Blood Marrow
Transplant. 2011;17:1404-1409.
6. Kayser S, Döhner K, Krauter J, et al. Impact of allogeneic transplantation
from matched related and unrelated donors on clinical outcome in
younger adult AML patients with FLT3 internal tandem duplications.
Blood. 2010;116: abstract 909.
7. Bornhauser M, Illmer T, Schaich M, et al. Improved outcome after
stem-cell transplantation in FLT3/ITD-positive AML. Blood. 2007;109:
2264-2265.
8. Sengsayadeth SM, Jagasia M, Engelhardt BG, et al. Allo-SCT for high-risk
AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the
conventional markers. Bone Marrow Transplant. 2012;47:1535-1537.
9. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should
be considered as an indicator for transplantation in acute myeloid
leukemia (AML): an analysis of 1135 patients, excluding acute pro-
myelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood.
2005;106:3658-3665.
10. Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem
duplication on the outcome of related and unrelated hematopoietic
transplantation for adult acute myeloid leukemia in ﬁrst remission: a
retrospective analysis. J Clin Oncol. 2012;30:735-741.
11. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of
the International Working Group for Diagnosis, Standardization of
M.R. Grunwald et al. / Biol Blood Marrow Transplant 20 (2014) 1989e1995 1995Response Criteria, Treatment Outcomes, and Reporting Standards for
Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:
4642-4649.
12. Nazha A, Cortes J, Faderl S, et al. Activating internal tandem duplication
mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete
response and relapse in patients with acute myeloid leukemia. Hae-
matologica. 2012;97:1242-1245.
13. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem
duplication and D835 mutations by a multiplex polymerase chain re-
action and capillary electrophoresis assay. J Mol Diagn. 2003;5:96-102.
14. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations
in 979 patients with acute myelogenous leukemia: association with
FAB subtypes and identiﬁcation of subgroups with poor prognosis.
Blood. 2002;99:4326-4335.
15. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the
FLT3 gene is a novel modality of elongation mutation which causes
constitutive activation of the product. Leukemia. 1998;12:1333-1337.
16. Walter RB, Gooley TA, Wood BL, et al. Impact of pre-transplantation
minimal residual disease, as detected by multiparametric ﬂow cytom-
etry, on outcome of myeloablative hematopoietic cell transplantation
for acute myeloid leukemia. J Clin Oncol. 2011;29:1190-1197.
17. Yin JA, O’Brien MA, Hills RK, et al. Minimal residual disease monitoring
by quantitative RT-PCR in core binding factor AML allows risk strati-
ﬁcation and predicts relapse: results of the United Kingdom MRC AML-
15 trial. Blood. 2012;120:2826-2835.
18. Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual
disease in NPM1-mutated acute myeloid leukemia: a study from the
German-Austrian acute myeloid leukemia study group. J Clin Oncol.
2011;29:2709-2716.
19. Schiller J, Praulich I, Krings Rocha C, Kreuzer KA. Patient-speciﬁc
analysis of FLT3 internal tandem duplications for the prognostication
and monitoring of acute myeloid leukemia. Eur J Haematol. 2012;89:
53-62.20. Abdelhamid E, Preudhomme C, Helevaut N, et al. Minimal residual
disease monitoring based on FLT3 internal tandem duplication in adult
acute myeloid leukemia. Leuk Res. 2012;36:316-323.
21. Scholl S, Loncarevic IF, Krause C, et al. Analyses of minimal re-
sidual disease based on Flt3 mutations in allogeneic peripheral
blood stem cell transplantation. J Cancer Res Clin Oncol. 2005;131:
279-283.
22. Scholl S, Loncarevic IF, Krause C, et al. Minimal residual disease based
on patient speciﬁc Flt3-ITD and -ITT mutations in acute myeloid leu-
kemia. Leuk Res. 2005;29:849-853.
23. Lin MT, Tseng LH, Beierl K, et al. Tandem duplication PCR: An ultra-
sensitive assay for the detection of internal tandem duplications of the
FLT3 gene. Diagn Mol Pathol. 2013;22:149-155.
24. Nakano Y, Kiyoi H, Miyawaki S, et al. Molecular evolution of acute
myeloid leukaemia in relapse: unstable N-ras and FLT3 genes
compared with p53 gene. Br J Haematol. 1999;104:659-664.
25. Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations
in paired presentation and relapse samples from patients with
acute myeloid leukemia: implications for the role of FLT3 mutations in
leukemogenesis, minimal residual disease detection, and possible
therapy with FLT3 inhibitors. Blood. 2002;100:2393-2398.
26. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in
relapsed acute myeloid leukemia: a comparative analysis of bone
marrow samples from 108 adult patients at diagnosis and relapse.
Blood. 2002;100:2387-2392.
27. Metzelder SK, Schroeder T, Finck A, et al. High activity of sorafenib
in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-
immune effects to induce sustained responses. Leukemia. 2012;26:
2353-2359.
28. Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD-
positive acute myeloid leukemia relapsing after allogeneic stem cell
transplantation with sorafenib. Biol Blood Marrow Transplant. 2011;17:
1874-1877.
